By Fineline Cube 
Shanghai Kehua Bioengineering Co., Ltd (SHE: 002022), a leading Chinese biotechnology company, has announced plans to develop a comprehensive medical production and innovation complex in Xi’an, Shaanxi province. This strategic initiative underscores the company’s commitment to expanding its footprint in the healthcare sector and enhancing its capabilities in medical equipment and diagnostic reagent manufacturing.
Project Details
The 90-acre development will encompass a state-of-the-art medical equipment and diagnostic reagent manufacturing base, alongside a healthcare industry innovation incubation center. The project is designed to be executed in two phases, with Phase 1 construction scheduled to commence by December 2025. Once fully operational, the facility is expected to achieve an annual production capacity of 72 million diagnostic test kits and 3,000 units of testing equipment, significantly boosting the company’s output and market presence.
Market Impact
This expansion is expected to strengthen Kehua Bioengineering’s position in the diagnostic reagent market, meeting the growing demand for high-quality medical diagnostic products. The facility’s advanced production capabilities and innovation incubation center will also contribute to the development of new technologies and products, further diversifying the company’s portfolio and enhancing its competitive edge.-Fineline Info & Tech